DDInter1042 DDInter1024
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Lapatinib {u} (Compound) treats {v} (Disease) breast cancer
Lapatinib {u} (Compound) binds {v} (Gene) TAP1
Lapatinib {u} (Compound) upregulates {v} (Gene) VAV3
Lapatinib {u} (Compound) downregulates {v} (Gene) PLOD3
Lapatinib {u} (Compound) causes {v} (Side Effect) Nail disorder
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propofol
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lapatinib (Compound) treats breast cancer (Disease)
Lapatinib (Compound) binds TAP1 (Gene)
Lapatinib (Compound) upregulates VAV3 (Gene)
Lapatinib (Compound) downregulates PLOD3 (Gene)
Lapatinib (Compound) causes Nail disorder (Side Effect)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Donepezil
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lapatinib may lead to a major life threatening interaction when taken with Macimorelin